|
Moderators: Dr. Francois Calaud, Dr. Mufid El Mistiri
|
|
1.30 pm - 1.35 pm
|
Welcome and Opening Remarks
|
Dr. Ussama Al Homsi,
Deputy Medical Director, Education, Research and Quality, Senior Consultant Medical Oncologist, NCCCR
|
|
1.35 pm - 2.00 pm
|
Breast Cancer -
Metastatic
(Abstract 1005): Fulvestrant plus capivasertib versus fulvestrant plus placebo after relapse or progression on an aromatase inhibitor in metastatic, estrogen receptor-positive breast cancer (FAKTION): Overall survival and updated progression free survival data with enhanced biomarker analysis
|
Dr. Salha Bujassoum
Chair of Medical Oncology and Palliative Care, Senior Consultant Medical Oncologist, NCCCR
|
|
2.00 pm - 2.25 pm
|
Breast Cancer - Local/Regional/Adjuvant (Abstract 507): Long-term outcomes of adjuvant denosumab in breast cancer: Fracture reduction and survival results from 3,425 patients in the randomised, double-blind, placebo-controlled ABCSG-18 trial
|
Dr. Francois Calaud
Senior Consultant Medical Oncologist, NCCCR
|
|
2.25 pm - 2.50 pm
|
Breast Cancer - Metastatic
(Abstract LBA3): Trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): results of DESTINY-Breast04 , a randomized, phase 3 study
|
Dr. Mufid El Mistiri
Senior Consultant Medical Oncologist, NCCCR
|
|
2.50 pm - 3.15 pm
|
Breast Cancer - Metastatic
(Abstract LBA1001): Primary Results From TROPiCS-02: A Randomized Phase 3 Study of Sacituzumab Govitecan (SG) vs Treatment of Physician’s Choice (TPC) in Patients (Pts) With Hormone Receptor-Positive/HER2-Negative (HR+/HER2-) Advanced Breast Cancer
|
Dr. Ahlam Yousif
Consultant Medical Oncologist, NCCCR
|
|
3.15 pm - 3.45 pm
|
Asr Prayer & Coffee Break
|
|
Moderators: Dr. Hind El Malik, Dr. Anas Hamad
|
|
3.45 pm - 4.10 pm
|
Gynecologic Cancer
(Abstract 5509): Dostarlimab in advanced/recurrent (AR) mismatch repair deficient/ microsatellite instability-high or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC): the GARNET study
|
Dr. Hind El Malik
Senior Consultant Medical Oncologist, NCCCR
|
|
4.10 pm - 4.35 pm
|
Care Delivery and Regulatory Policy
(Abstract 1563): Clinical development of new drugs for adults and children with cancer in 2010-2020: Longitudinal study of investigational drugs
|
Dr. Nabil Omar,
Clinical Pharmacist,
NCCCR
|
|
4.35 pm - 5.00 pm
|
Developmental Therapeutics - Immunotherapy(Abstract 2507): Single-cell profiling of human heart and blood in immune checkpoint inhibitor-associated myocarditis
|
Ms. Asma Younus,
Clinical Nurse Specialist
NCCCR
|
|
5.00 pm - 5.25 pm
|
Symptoms and Survivorship(Abstract 12023): Vitamin D insufficiency as a peripheral neuropathy risk factor in white and black patients in SWOG 0221
|
Ms. Wafaa Shehada & Ms. Shaikha Al Keldi,
Clinical Nurse Specialist
NCCCR
|
5.25 pm - 5.50 pm
|
Symptoms and Survivorship(Abstract 12022): Oral minoxidil for the treatment of late alopecia in cancer survivors
|
Ms. Wafa Alsaadi
Clinical Nurse Specialist
NCCCR
|
|
5.50 pm - 6.15 pm
|
Symptoms & Survivorship
(Abstract 12000): Impact of acetaminophen on the efficacy of immunotherapy in cancer patients
|
Dr. Anas Hamad,
Director of Pharmacy,
NCCCR
|
|
6.15 pm - 7.10 pm
|
Maghrib Prayer & Dinner Break
|
|
Moderators: Dr. Asma El Hassan, Dr. Ussama Al Homsi
|
|
7.10 pm - 7.35 pm
|
Sarcoma
(Abstract LBA2): Phase III assessment of topotecan & cyclophosphamide and high-dose ifosfamide in rEECur, an international randomised controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES)
|
Dr. Asma El Hassan,
Senior Consultant Medical Oncologist, NCCCR
|
|
7.35 pm - 8.00 pm
|
Melanoma/Skin Cancers
(Abstract LBA9500): Distant metastasis-free survival with pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: the phase 3 KEYNOTE-716 study
|
Dr. Ashraf Awad,
Associate Consultant Medical Oncologist, NCCCR
|
